Skip to content

Development and evaluation of an algorithm in Medication Management for best practice. Effectiveness of the intervention and translation into standard care for nursing home residents-AMBER study

Development and evaluation of an algorithm in Medication Management for best practice. Effectiveness of the intervention and translation into standard care for nursing home residents-AMBER study - AMBER-Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00010995
Enrollment
100
Registered
2017-08-23
Start date
2017-08-25
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multimorbidity

Interventions

Group 1: A Medication Management for residents of nursing homes will be performed by pharmacists in collaboration with physicians and nurses by means of an innovative algorithm. There is no control gr

Sponsors

Elefanten-Apotheke
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: Residency in a nursing home facility, multimorbidity (at least 2 chronic diseases), polymedication (at least 5 chronic systemic available medications), signed informed consent

Exclusion criteria

Exclusion criteria: participation in other clinical studies at present time

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the reduction of the detected drug-related problems (DRPs), using the algorithm. DRPs are measured at time of the Medication Review (t0) and classified according PCNE (Pharmaceutical Care Network Europe) version 8.01. A follow-up is performed three month after the intervention (t1).

Secondary

MeasureTime frame
- Drug-related problems classified according to PCNE version 8.01 (number and type) - Measurement of physicians’ and nurses’ acceptance by using an acceptance form, classified according to PCNE version 8.01 - Number of drug-related problems classified according to PCNE version 8.01, detected by an Advanced Medication Review - Reproducibility of analysis and feasibility of the algorithm (feedback survey, time spending, inter-rater reliability)

Countries

Germany

Contacts

Public ContactSusanne Erzkamp

Elefanten-Apotheke

amber-study@gmx.de02551 5435

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 25, 2026